Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan

被引：3
作者：
Yun, Karen M. [1 ]
Bazhenova, Lyudmila [1 ]
机构：
[1] UC San Diego Hlth, Div Hematol Oncol, Moores Canc Ctr, La Jolla, CA 92122 USA
来源：
BMJ CASE REPORTS | 2023年 / 16卷 / 05期
关键词：
Lung cancer (oncology); Therapeutic indications; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2; GENE; IMMUNOHISTOCHEMISTRY; EXPRESSION; HER-2/NEU; SURVIVAL; MUTATION;
D O I：
10.1136/bcr-2022-253260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    Gatzemeier, U
    Groth, G
    Butts, C
    Van Zandwijk, N
    Shepherd, F
    Ardizzoni, A
    Barton, C
    Ghahramani, P
    Hirsh, V
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 19 - 27
  • [42] CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Park, Sun Hoo
    Park, Jong Heon
    Lee, Jae Cheol
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 247 - 253
  • [43] Trastuzumab deruxtecan for HER2+advanced breast cancer
    Lee, Jiyun
    Park, Yeon Hee
    FUTURE ONCOLOGY, 2021, 18 (01) : 7 - 19
  • [44] A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer
    Sur, Daniel
    Lungulescu, Cristina
    Dumitrescu, Elena Adriana
    Afrasanie, Vlad
    Spinu, Stefan
    Lungulescu, Cristian Virgil
    Schmoll, Hans-Joachim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 633 - 641
  • [45] Rare mutations in non-small-cell lung cancer
    D'Arcangelo, Manolo
    D'Incecco, Armida
    Cappuzzo, Federico
    FUTURE ONCOLOGY, 2013, 9 (05) : 699 - 711
  • [46] Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
    Abu Al Karsaneh, Ola
    Al Anber, Arwa
    ALQudah, Mohammad
    Al-Mustafa, Sahar
    AlMa'aitah, Hussien
    Sughayer, Maher
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
  • [47] Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer
    Al-Obeidi, Ebaa
    Li, Tianhong
    Kelly, Karen
    CLINICAL LUNG CANCER, 2020, 21 (01) : E15 - E20
  • [48] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Verschoor, Noortje
    Smid, Marcel
    Jager, Agnes
    Sleijfer, Stefan
    Wilting, Saskia M.
    Martens, John W. M.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [49] Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
    Riudavets, M.
    Sullivan, I.
    Abdayem, P.
    Planchard, D.
    ESMO OPEN, 2021, 6 (05)
  • [50] Specific organ metastases and survival in metastatic non-small-cell lung cancer
    Tamura, Tomohiro
    Kurishima, Koichi
    Nakazawa, Kensuke
    Kagohashi, Katsunori
    Ishikawa, Hiroichi
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (01) : 217 - 221
12345